Actively Recruiting

Age: 18Years +
All Genders
ID03837574

French National Registry of Patients With Tetralogy of Fallot and Implantable Cardioverter Defibrillator

Led by Paris Sudden Death Expertise Center · Updated on 2019-02-12

150

Participants Needed

1

Research Sites

595 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This research aims to collect and analyze data from patients with tetralogy of Fallot who have an implantable cardioverter defibrillator (ICD) for either primary or secondary prevention. The study is a national French registry that includes both retrospective cases before 2010 and prospective cases after 2010 with ongoing follow-up. The goal is to better understand ventricular arrhythmias and complications related to ICDs in this specific population. Patients included in this registry are those with tetralogy of Fallot who have an ICD implanted. French centers that perform ICD implantations are contacted yearly to include all eligible patients. The study collects all baseline electrocardiograms (ECG) and reviews endocavitary electrograms (EGM). Events are centrally reviewed and adjudicated to ensure consistent data collection. Participants are followed prospectively with annual updates to monitor the occurrence of ventricular arrhythmias and ICD-related complications. The registry tracks these outcomes for an average of one year after enrollment. This observational study involves no intervention beyond routine clinical care and aims to gather comprehensive data on this patient group over time.

CONDITIONS

Brief Title

French National Registry of Patients With Tetralogy of Fallot and Implantable Cardioverter Defibrillator

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Have a diagnosis of tetralogy of Fallot
  • Have an implantable cardioverter defibrillator (ICD) implanted
  • Be 18 years of age or older
Not Eligible

You will not qualify if you...

  • Are younger than 18 years old

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

Long-term Monitoring

Duration - Up to 20 years

Participants with tetralogy of Fallot and an implantable cardioverter defibrillator are observed with annual updates and follow-up to track ventricular arrhythmias and device complications.

Annual visits

Trial Site Locations

Total: 1 location

1

Paris Sudden Death Expertise Center

Paris, France, 75015

Actively Recruiting

Loading map...

Research Team

V

Victor Waldmann, MD

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Similar Trials

A 10-Minute Cardiovascular Magnetic Resonance Protocol for C...

Coronary Artery Disease

Actively Recruiting

1 location

Evaluation of Surgical Techniques and Outcomes Across the Li...

Congenital Heart Disease

Actively Recruiting

1 location

A Comprehensive Registry Study of the Whole Life Cycle of Pa...

Congenital Heart Disease

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Published Research Related To This Trial

Rapid ventricular tachycardia in patients with tetralogy of Fallot and implantable cardioverter-defibrillator: Insights from the DAI-T4F nationwide registry.

Mikael Laredo, Guillaume Duthoit, Frédéric Sacher...

https://pubmed.ncbi.nlm.nih.gov/36309156

Sex Differences in Outcomes of Tetralogy of Fallot Patients With Implantable Cardioverter-Defibrillators.

Victor Waldmann, Abdeslam Bouzeman, Guillaume Duthoit...

https://pubmed.ncbi.nlm.nih.gov/36266008

Subcutaneous vs Transvenous Implantable Cardioverter-Defibrillator Therapy in Patients With Tetralogy of Fallot.

Victor Waldmann, Christelle Marquié, Abdeslam Bouzeman...

https://pubmed.ncbi.nlm.nih.gov/36265962

Impact of Pulmonary Valve Replacement on Ventricular Arrhythmias in Patients With Tetralogy of Fallot and Implantable Cardioverter-Defibrillator.

Francis Bessière, Kévin Gardey, Abdeslam Bouzeman...

https://pubmed.ncbi.nlm.nih.gov/33933408

Long-Term Follow-Up of Patients With Tetralogy of Fallot and Implantable Cardioverter Defibrillator: The DAI-T4F Nationwide Registry.

Victor Waldmann, Abdeslam Bouzeman, Guillaume Duthoit...

https://pubmed.ncbi.nlm.nih.gov/32998542